We Offer Worldwide Shipping
Login Wishlist

Wogonin

$78

  • Brand : BIOFRON

  • Catalogue Number : BF-W3004

  • Specification : 98%

  • CAS number : 632-85-9

  • Formula : C16H12O5

  • Molecular Weight : 284.26

  • PUBCHEM ID : 5281703

  • Volume : 25mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-W3004

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

284.26

Appearance

Yellow crystalline powder

Botanical Source

Leonurus japonicus,Scutellaria baicalensis,Dictamnus dasycarpus,Croton crassifolius,Dioscorea spongiosa

Structure Type

Flavonoids

Category

Standards;Natural Pytochemical;API

SMILES

COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)O

Synonyms

Norwogonin 8-methyl ether/5,7-DIHYDROXY-8-METHOXYFLAVON/5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-on/Wogonin/5,7-Dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one/5,7-dihydroxy-8-methoxy-2-phenyl-chromen-4-one/4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-/5,7-dihydroxy-8-methoxyflavone/vogonin/WOOGONIN/WILDYAMP.E

IUPAC Name

5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one

Density

1.4±0.1 g/cm3

Solubility

Methanol; Ethanol

Flash Point

198.4±23.6 °C

Boiling Point

518.8±50.0 °C at 760 mmHg

Melting Point

203-206°C

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:632-85-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

31298148

Abstract

Diabetes Mellitus (DM) is now a well-known factor which initiates many metabolic derangements in various tissues and organs including liver, muscle, pancreas, adipose tissue, cardiovascular and nervous system. Cardiovascular complications are the most crucial , and their effects are so intensive that their derangement leads to cardiac failure even in the absence of ischemic heart diseases. This entity of cardiac pathology in DM is often regarded as diabetic cardiomyopathy (DCM). Recently, many plant-derived drugs have been tested to control and alleviate DCM. Wogonin is one of the drugs the characteristics of which have been deeply studied. Wogonin is a flavonoid having yellow color pigment in their leaves and is obtained from the roots of plant Scutellaria Baicalensis Georgi. Wogonin has long been used as an active anti-cancer drug in Chinese medicine practice. In recent past wogonin has shown to possess notable anti-inflammatory, and anti-allergic properties. Wogonin has demonstrated to possess anti-oxidant, anti-viral, anti-inflammatory and also anti-thrombotic properties. Wogonin has shown to alleviate apoptosis, and ER stress in the cells and this property can also be used in the treatment of cardiovascular diseases. Notably, wogonin has been documented to have an extensive margin of safety as well as displays little or no organ toxicity following extended intravenous administration. In this review, we discuss recently discovered therapeutic potential of wogonin in the treatment of DCM.

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

KEYWORDS

Diabetic cardiomyopathy; ER stress; diabetes mellitus; hyperglycemia; inflammation; wogonin.

Title

Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?

Author

Khan S1, Kamal MA2,3,4.

Publish date

2019

PMID

29200200

Abstract

Acute kidney injury (AKI), characterized by aggressive inflammatory responses and destruction of renal resident cells, can cause abrupt kidney dysfunction. To date, effective therapy for AKI is lacking. In this study, we evaluated the renoprotective effect of wogonin, an herbal active compound, using a cisplatin-induced AKI mouse model. In vivo results show that wogonin substantially suppressed the increased levels of serum creatinine and blood urea nitrogen (BUN) almost to the normal level. Wogonin also attenuated tubular damage, shown by PAS staining, electron microscopy and molecular analysis of KIM-1. In addition, wogonin suppressed kidney inflammation as indicated by a >60% decrease in macrophage infiltration, a >50% reduction in inflammatory cytokine production and inhibited NF-κB activation in the injured kidney. Mechanistically, molecular docking results show that wogonin effectively inhibited RIPK1 by occupying the ATP-binding pocket of the enzyme, which is a key regulator of necroptosis. Moreover, inhibition of RIPK1, or RIPK3, reversed the protective effects of wogonin in cisplatin-treated HK2 cells, indicating wogonin works in a RIPK1/RIPK3-dependent manner. Surprisingly, wogonin enhanced the anti-proliferative effect of cisplatin on human hepatoma HepG2 cells. Thus, our findings suggest wogonin may be a renoprotective adjuvant for cisplatin-based anticancer therapy.

Title

Wogonin protects against cisplatin-induced acute kidney injury by targeting RIPK1-mediated necroptosis.

Author

Meng XM1,2,3, Li HD1, Wu WF1, Ming-Kuen Tang P4, Ren GL1, Gao L1, Li XF1,2, Yang Y1,2, Xu T1,2,3, Ma TT1,2,3, Li Z1,2,3, Huang C1,2,3, Zhang L1,2,3, Lv XW1,2,3, Li J1,2,3.

Publish date

2018 Jan

PMID

32132930

Abstract

Osteoarthritis (OA) is a degenerative joint disease characterized by inflammatory degradation of articular cartilage and subchondral bone. Wogonin, a compound extracted from the plant Scutellaria baicalensis (colloquially known as skullcap), has previously been shown to have direct anti-inflammatory and antioxidative properties. We examined the pain-reducing, anti-inflammatory, and chondroprotective effects of wogonin when applied as a topical cream. We validated the efficacy of delivering wogonin transdermally in a cream using pig ear skin in a Franz diffusion system. Using a surgical mouse model, we examined the severity and progression of OA with and without the topical application of wogonin. Using a running wheel to track activity, we found that mice with wogonin treatment were statistically more active than mice receiving vehicle treatment. OA progression was analyzed using modified Mankin and OARSI scoring and direct quantification of cyst-like lesions at the chondro-osseus junction; in each instance we observed a statistically significant attenuation of OA severity among mice treated with wogonin compared to the vehicle treatment. Immunohistochemistry revealed a significant decrease in protein expression of transforming growth factor β1 (TGF-β1), high temperature receptor A1 (HTRA1), matrix metalloprotease 13 (MMP-13) and NF-κB in wogonin-treated mice, further bolstering the cartilage morphology assessments in the form of a decrease in inflammatory and OA biomarkers.

Copyright © 2020 Smith, Starr, Goodman, Hanson, Palmer, Woolstenhulme, Weyand, Marchant, Bueckers, Nelson, Sterling, Rose, Porter, Eggett and Kooyman.

KEYWORDS

HTRA1; MMP-13; NF-κB; TGF-β1; inflammation; osteoarthritis; wogonin

Title

Topical Application of Wogonin Provides a Novel Treatment of Knee Osteoarthritis.

Author

Smith JF1, Starr EG1, Goodman MA1, Hanson RB1, Palmer TA1, Woolstenhulme JB1, Weyand JA1, Marchant AD1, Bueckers SL1, Nelson TK1, Sterling MT1, Rose BJ1, Porter JP1, Eggett DL2, Kooyman DL1.

Publish date

2020 Feb 18


Description :

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.